| Abstract: |
This chapter reviews the pathobiology of diffuse large B-cell lymphoma (DLBCL) as well as consideration regarding staging, management, and prognosis. It presents a series of multiple choice and discussion questions, and answers on the DLBCL. The chapter commences with a discourse on the expertise of a hematopathologist in the diagnosis of non-Hodgkin's lymphoma (NHL), and ends with the treatment of early-stage DLBCL. It also discusses on the role of the International Prognostic Index (IPI) model in the rituximab era, the data behind R-CHOP in DLBCL, and the approach in patients with hepatitis B virus (HBV) infection and DLBCL. In addition, the chapter tabulates the heterogeneity of the DLBCL. © 2014 John Wiley and Sons, Inc. |
